Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > TOP STORIES
TOP STORIES
-
REGULATORY Novartis’ Radioligand Therapy, More Meds Inch Closer to Japan Approval with Panel OK
August 25, 2025
-
REGULATORY PMDA’s “Early Considerations” Start to Pay Off with Faster Reviews
August 22, 2025
-
REGULATORY Japan Mulls Preferential R&D Tax Credits for Strategic Technologies in FY2026 Reform Talks
August 22, 2025
-
ORGANIZATION Hemp Cannabinoid Consortium Draws 40 Inquiries from Industry and Academia
August 22, 2025
-
BUSINESS Linepharma Japan Eyes Ophthalmology as Second Pillar to Women’s Health
August 22, 2025
-
REGULATORY AMED to Put Practicality First in Project Selection: Ecosystem Coordinator
August 21, 2025
-
BUSINESS Itochu Launches J-STEP to Help Overseas Drug Makers Tackle Japan’s “Drug Loss”
August 21, 2025
-
BUSINESS Alloy Japan Looks to Turn iCAR-T into Shared Infrastructure, IND Filing Slated for 2026
August 20, 2025
-
BUSINESS Keytruda Retains Top Spot in Japan Drug Market in April-June: IQVIA
August 20, 2025
-
REGULATORY Japan Weighs Legal Framework for Pharmaceutical Data Protection; JPMA Sees Opportunity for Reform
August 19, 2025
-
REGULATORY Japan Approves First SGLT2 Generics, 12 Firms Pile into Vimpat Ahead of December Listing
August 18, 2025
-
REGULATORY Novartis’ Radioligand Therapy, Other New Meds Up for Japan Panel Review on Aug. 22
August 12, 2025
-
REGULATORY Japan Nears Approval for 1st Biosimilars of Actemra, Simponi, and Ranmark
August 12, 2025
-
REGULATORY Japan Approves FY2026 Budget Guidelines, Natural Increase at 400 Billion Yen
August 12, 2025
-
BUSINESS Ashraf Al-Ouf Named President of Bayer Yakuhin and Bayer Holding in Japan
August 8, 2025
-
REGULATORY Public-Private Council WG to Focus on Innovation Evaluation for FY2026 Reform: Official
August 8, 2025
-
BUSINESS Sumitomo Eyes Conditional Nod for iPS Cell Therapy for Parkinson’s in FY2025
August 8, 2025
-
BUSINESS PeptiDream Probes Ex-COO over Unauthorized Provision of Reagents to Academia
August 8, 2025
-
REGULATORY Industry Urges “Objective Review First” for CEA Reform; Payers Push for Expansion
August 7, 2025
-
REGULATORY Welireg, Airwin, Talvey and More Set for NHI Listing; Premiums Wiped Out by “Zero” Rule
August 7, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…